A prospective, randomized, double-blind, and multicenter trial of prophylactic effects of ramosetron on postoperative nausea and vomiting (PONV) after craniotomy: comparison with ondansetron

Table 2 Incidences of PONV and rescue antiemetics

	Group A (n = 41)	Group B (n = 44)	Group C (n = 42)	P value
Postoperative 0–48 h
Nausea	24 (59)	18 (41)	6 (14) ^{† ‡}	< 0.001
Retching & Vomiting	9 (22)	9 (20)	3 (7)	0.13
Complete response	15 (37)	26 (59)	35 (83) ^†	< 0.001
Rescue antiemetic	11 (27)	9 (20)	1 (2) ^{† ‡}	0.008
Postoperative 0–2 h
Nausea	6 (15)	5 (11)	2 (5)	0.318
Retching & Vomiting	1 (2)	1 (2)	1 (5)	0.999
Complete response	34 (83)	40 (91)	40 (95)	0.172
Rescue antiemetic	2 (5)	3 (7)	0 (0)	0.249
Postoperative 2–24 h
Nausea	17 (41)	12 (27)	3 (7) ^{† ‡}	0.001
Retching & Vomiting	6 (15)	8 (18)	2 (2)	0.154
Complete response	23 (56)	33 (75)	38 (86) ^†	0.002
Rescue antiemetic	8 (20)	5 (11)	1 (2) ^†	0.045
Postoperative 24–48 h
Nausea	16 (39)	14 (32)	4 (10) ^†	0.006
Retching & Vomiting	4 (10)	5 (11)	0 (0)	0.088
Complete response	25 (61)	30 (68)	38 (90) ^†	0.006
Rescue antiemetic	5 (12)	6 (14)	0 (0)	0.050

Group A; ondansetron 4 mg group. Group B; ondansetron 8 mg group. Group C; ramosetron 0.3 mg group. Values are expressed as number of the patients (%). ^†: <0.0175 compared with Group A. ^‡: 0.0175 compared with Group B.

ISSN: 1471-2253